Altizide is a thiazide diuretic. In combination with spironolactone it is sold under the brand name of Aldactacine and Aldactazine by Pfizer and other names by other companies. Technically, altizide is a benzothiadiazine-derived agent that inhibits the sodium-chloride cotransporter in the distal renal tubule, producing natriuresis and increased urinary water and chloride excretion with a consequent reduction in plasma volume and blood pressure; it is typically formulated as an oral solid dosage form and is handled and assayed using standard pharmaceutical quality systems including validated HPLC and chromatographic assays. It is a white to off-white crystalline powder with limited aqueous solubility, is chemically stable under recommended storage conditions when protected from moisture and heat, and is subject to batch release testing for assay, related-substance profile, residual solvents and heavy metals.
Parent: Altizide
Parent: Hydrochlorothiazide/ Benzothiadiazine/ Altizide
Typical manufacturer specifications used in commercial and regulatory dossiers call for assay on a dry basis of about 98.0 to 102.0 percent and control of related substances such that any single unidentified impurity is not more than 0.2 percent and total impurities are not more than 1.0 percent, with specified known impurities limited based on their toxicological qualification; common related compounds and impurities monitored include hydrolysis products, desulfonylated or ring-opened degradation products, residual synthetic intermediates and unreacted starting materials, and residual solvents which are controlled to limits consistent with ICH Q3C; analytical control is normally performed by validated HPLC for related substances, GC for volatile organic impurities and ICP or comparable methods for elemental impurities.
Altizide is a thiazide diuretic that acts on the distal renal tubule to inhibit the sodium-chloride cotransporter and promote natriuresis
Altizide reduces sodium and chloride reabsorption in the distal convoluted tubule, increasing renal excretion of sodium, chloride and water, which lowers circulating volume and reduces arterial blood pressure over time.
Typical commercial specifications include assay 98.0 to 102.0 percent (dry basis), individual unspecified impurities not greater than 0.2 percent and total impurities not greater than 1.0 percent, with specified impurity limits set according to their identity and toxicological qualification and residual solvents and metals controlled per ICH guidance.
Related substances are commonly monitored by validated HPLC methods, residual solvents by GC, and elemental impurities by ICP-MS or ICP-OES, supplemented by identity tests and dissolution or disintegration testing for finished dosage forms.
Yes, altizide is combined with potassium-sparing agents such as spironolactone and is marketed under brand names including Aldactacine and Aldactazine by Pfizer and under other trade names by other manufacturers.
